# Glakolens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glakolens

- Industry: Medical Devices & Equipment
- Headquarters: Istanbul, Turkey
- Website: www.glakolens.wordpress.com
- Total disclosed funding: $0.5M
- Latest round: Seed (May 24, 2017)
- Investors on record: 1

## About

GlakoLens specializes in the creation of non-invasive biosensors integrated into contact lenses, enabling users to monitor health metrics such as glucose levels effectively and discreetly.Founded by Arda Yalcinkaya, Gunhan Dundar, and Hamdi Torun, GlakoLens operates out of Istanbul, Turkey. The company focuses on innovative health monitoring solutions through contact lenses designed for users managing diabetes and similar health conditions. In May 2017, GlakoLens raised EUR 0.470 million in Seed funding led by ACT Venture Partners, marking its first investment round and bringing the total amount raised to EUR 0.470 million.GlakoLens primarily focuses on the development of non-invasive biosensors that are embedded in contact lenses. These innovative biosensors are designed to monitor various health metrics, providing users with real-time data that can help manage conditions such as diabetes and other health-related issues. The core functionality of these products includes the ability to detect biochemical markers through the tear fluid, offering a seamless integration of health monitoring into daily life without the need for traditional invasive procedures. The company targets health-conscious consumers and individuals with specific medical needs, ensuring that their products cater to both everyday wearers and those requiring continuous health monitoring. Currently, GlakoLens aims to introduce its products to markets in North America and Europe, where there is a growing demand for health-monitoring technologies.The revenue model for GlakoLens is centered around direct-to-consumer sales and potential partnerships with healthcare providers and retail distributors. The company anticipates transactional structures that may involve consumers purchasing their biosensor contact lenses through online platforms or authorized retailers. Flagship products are expected to be priced competitively within the health tech market, catering to various consumer segments, including individuals managing chronic health conditions and proactive health enthusiasts. Revenue generation will also be supported by collaborations with healthcare institutions that may integrate GlakoLens products into their patient care protocols. By establishing these partnerships, GlakoLens aims to enhance market penetration and customer acquisition while ensuring a sustainable revenue stream.GlakoLens is focused on expanding its product line with new biosensing technologies set to launch in the upcoming year. The company is strategically targeting North American and European markets for expansion, with plans to establish a presence by the end of 2024. The recent Seed funding of EUR 0.470 million will be utilized to support product development and market entry strategies, enhancing the company's capabilities in delivering innovative health monitoring solutions.

## Funding rounds

- Seed, May 24, 2017, $0.5M — ACT Venture Partners

## Investors

- ACT Venture Partners (https://capitalatlas.ai/funds/act-venture-partners) — Seed